the use of BMP in the pediatric population by using a large administrative database. Furthermore, we aimed to perform an analysis of acute complications and adverse events associated with the use of BMP in this population. In addition, we have performed a review of the literature regarding BMP use for pediatric spinal fusion. We hypothesize that the use of rhBMP-2 in children is not associated with a higher risk of acute complications in pediatric spinal fusion.
Methods

Review of the Literature
Search Strategy. A search of PubMed (1966 PubMed ( -2013 , Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials , and Google Scholar databases was conducted to identify articles of interest. These databases were searched using the key words "spine," "spine fusion," "cervical spine," "cervical spine fusion," "thoracic," or "lumbar" combined with "bmp," "bmp 2," "bmp 7," "bone morphogenic protein," "bone morphogenetic protein," or "allograft" and "pediatric," "pediatric use," "child," "childhood," or "children."
Searches were limited to the English language and to clinical studies rather than basic science data. The reference sections of included studies were also searched to identify relevant articles. The search was performed independently by 2 authors (B.G.R., Y.L.) and the results were combined.
Study Selection. Search results were first screened by title and abstract. The abstracts of articles of interest were reviewed in detail. Case series, cohort studies, clinical trials, meta-analyses, and systematic reviews were all deemed eligible for inclusion. Individual case reports were excluded from this analysis (fewer than 5 individual case reports excluded). In addition, studies focusing on adult populations were excluded.
Institutional Database
We retrospectively analyzed the PearlDiver Technologies' private payer database containing all orthopedicrelated diagnosis and procedure codes from all United HealthCare patient records from 2005 to 2011. United HealthCare is the largest private insurance carrier in the US, covering more than 70 million people in all 50 states. Detailed information about the geographic distribution of covered individuals is not available. The ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) procedure codes that identified patients who underwent spinal fusion are found in Table 1 . The ICD-9-CM code 84.52 and CPT code 20930 were used to specifically identify patients who underwent spinal fusion with BMP. The absence of this code implied that the fusion was done without the use of BMP (control cohort). Available covariates reported in the database were sex and age (grouped as age less than 10 or age 10-19 years). Each patient was only enrolled once. Data capture includes both the initial hospital encounter and 90-day follow-up of each patient. Follow-up data are captured if the encounter includes at least one of the more than 2000 diagnosis or procedure codes considered orthopedic-related by the PearlDiver database. This includes all codes for neoplasm, hematoma, diabetes, atherosclerosis, embolism, arthritis, arthropathy, trauma, bone and joint disease, rheumatism, and complications. (See Appendix for a comprehensive list of included codes.) The privacy policy of PearlDiver Technologies, Inc., does not allow population of a given field in a database query if there are fewer than 11 patients who would meet those specific criteria. Therefore, some fields of inquiry cannot be evaluated. The University of Wisconsin Institutional Review Board provided exemption for this project.
Postoperative Complications
The ICD-9-CM diagnosis codes identified complications in the patient cohorts that occurred during the initial hospital stay and in the subsequent 90-day follow-up in which an orthopedic diagnosis or procedure code was entered. Patient data are available longitudinally as long as the patient remains insured by United HealthCare. Longitudinal follow-up on patients who change insurance providers is not available.
Complications were categorized into 13 groups: cardiac; respiratory; peripheral vascular; central nervous system; hematoma; accidental cut, puncture, or hemorrhage during procedure; complications of operative wound; postoperative infection; other; CSF leak; deep vein thrombosis; mechanical complication of implant or graft; and death (Table 2) .
Repeat Operations
The ICD-9 procedural codes were used to identify reoperations within 90 days of the index procedure. A list of ICD-9 codes commonly associated with reoperations was developed from a database search at the senior author's institution (Table 3) .
Statistical Analysis
Chi-square analysis was used to compare the overall complication rates between the 2 treatment groups. Relative risk values and 95% confidence intervals were determined for the association of any complication with BMP usage compared with control. Statistical significance was defined as a Type I error (a) < 0.05.
Results
Literature Review
Our review of the literature identified 8 studies addressing the use of BMP with pediatric spinal fusion (see Table 4 ). Dodwell et al. used the KID, which is a sample of 4121 US hospitals, and identified 8289 spinal fusions performed in children in 2009; 6 BMP was used in 9.2% of these cases. In-hospital complications occurred in 3.0% of cases in which BMP was used and in 3.6% of cases in which no BMP was used. This difference was not statistically significant. Use of BMP was associated with older age, lumbosacral level of arthrodesis, fewer vertebrae fused, spondylolisthesis, neurofibromatosis, and surgery performed in the Midwest. Use of BMP was less likely in patients with Medicare or Medicaid health coverage and those treated in specialized pediatric hospitals. Because this sample was drawn from an inpatient database, only those complications that occurred during the initial hospital stay were captured.
Similar findings are reported in another study of the KID records for [2003] [2004] [2005] [2006] [2007] [2008] [2009] . 10 Like Dodwell and colleagues, Jain et al. 10 report 9.3% overall BMP use in 2009, but also note a steady increase in BMP use, from 2.7% in 2003. Use of BMP in this study was more common with thoracolumbar fractures, patients with spondylolisthesis, private insurance, nonteaching hospitals, and no use of autograft. No analysis of complications was performed in this study.
A report from the Scoliosis Research Society Morbidity and Mortality (SRS M&M) Committee examined the incidence of perioperative complications in 55,862 cases of spinal fusion with and without BMP. 19 Of these cases, 17,513 were pediatric scoliosis operations, and 9% (1576) used BMP. This rate of BMP use is consistent with the rate reported by Dodwell et al. The complication rate for these patients was 7.0% without BMP and 8.8% with BMP (difference not statistically significant). Unlike the KID database, the SRS M&M database contains data entered by the primary surgeon. Therefore, it may be affected by a selection bias, but it also contains follow-up data, rather than only information about the initial hospitalization and in-hospital complications.
A series of 81 pediatric patients underwent 91 orthopedic procedures including the use of BMP. 13 This included indications other than spine surgery, but the majority of procedures (52) were spinal fusion. In the total cohort, there were 9 operative site complications and 7 other complications (17.5% total complication rate). The authors note no systemic toxicity and no excessive bone growth. A patient with optic glioma had enlargement of the tumor, and another patient developed dural fibrosis requiring reoperation after BMP exposure.
A single-center case series of 48 patients, ages 3 to 18 years, undergoing occipital cervical decompression and fusion with rhBMP (4.2 mg, INFUSE; Medtronic, Inc.) found 6 complications that were presumed to be related to the use of BMP. 12 Five of these were epidural fluid collections, with 2 requiring operative intervention for neurological compromise. Although there is no comparison group in this publication, the authors note that in their previous experience with this procedure in this population of patients, no epidural fluid collections had been encountered. They conclude that the use of rhBMP was the most likely factor leading to this complication.
In contrast, another single center reviewed 17 cases of pediatric spinal arthrodesis, 7 of which included the occiput. 1 These authors concluded that no BMP-related complications occurred.
A third single-institution study included 19 patients undergoing occipitocervical, cervical, thoracic, lumbar, or lumbosacral fusion with BMP. 7 There was 1 case of bony overgrowth causing neural compression and requiring reoperation. There were also 2 superficial wound infections.
Finally, in a series of 11 patients with neuromuscular scoliosis, deemed to be high risk for pseudarthrosis at L5-S1, BMP was used at that level only in the setting of a long fusion to the pelvis. 9 One patient had a pseudarthrosis and one had a wound infection. There were no other identified BMP-related complications. 
Database Query
Utilization of BMP. A total of 4658 pediatric patients underwent spinal fusion between 2005 and 2011. The majority of the patients were female (3048, 65.44%), and the vast majority of the patients were between 10 and 19 years of age (4424, 94.98%). There were 234 patients (5.02%) younger than 10 years. Further subdivision of patient ages was not possible using the PearlDiver database. Thoracolumbar fusion surgery accounted for 4338 (93.13%) of the operations, with anterior and posterior cervical surgery accounting for the remainder of the database entries. There were 193 anterior cervical fusion operations. The exact number of posterior cervical operations was not available. Table 5 shows the sex, age, and location of surgery.
Of the 4658 pediatric patients who underwent spinal fusion, 1752 (37.6%) had operations in which BMP was used. A higher proportion of female patients compared with male patients undergoing spinal fusion had operations in which BMP was used (39.4% vs 34.2%, p = 0.001). The rate of BMP use was exactly the same in patients less than 10 years compared with those 10-19 years (37.6%, p = 0.998).
Thoracolumbar spinal fusions comprised the majority of operations in the database. Of the 4338 thoracolumbar fusion operations, 1714 (39.5%) used BMP. There was no difference in BMP use comparing male with female patients undergoing thoracolumbar fusion (male 39.4%, female 40.5% BMP use; p = 0.499). Likewise, there was no difference between patients less than 10 years compared with those 10-19 years who underwent thoracolumbar fusion (39.8% vs 39.5% BMP use, p = 0.996).
Regarding anterior cervical fusions, 14 of 193 patients (7.3%) had documented BMP use. This is a significantly lower rate than for thoracolumbar fusions (39.5%, p < 0.0001). Insufficient details are available to compare male and female patients in this group. In patients less than 10 years of age, 2 of 10 had fusions in which BMP was used, compared with 12 of 183 patients 10-19 years old (20% vs 6.6%, p = 0.111).
Thirty-five patients underwent posterior cervical fusion in which BMP was used. Data regarding posterior cervical fusion without BMP are not available due to the PearlDiver privacy policy (fewer than 11 cases).
Complications. Of the 1752 cases in which spinal fusion involved BMP, 172 patients (9.8%) had a complication. Of the 2906 patients without BMP, 287 (9.9%) had a complication (Fig. 1) . This difference was not statistically significant (p = 0.948). The complication rate for male patients was 11.4% in those with BMP versus 10.7% in those without BMP. For female patients, complications with BMP occurred in 9.1% versus 9.4% in those without BMP. Neither of these differences was statistically significant (p = 0.641 for male patients, p = 0.749 for female patients). The difference between the percentage of male and female patients treated with BMP was also not significant.
Insufficient data are available to analyze the complication rate for anterior or posterior cervical spinal fusions. Considering only thoracolumbar fusions, the complication rate is almost identical to the complication rate for the entire sample. This is not surprising, given the large proportion of the sample that is made up of thoracolumbar fusions.
We have attempted to better characterize complications by grouping them into systemic, wound, CNS, and other complications. Among the 1752 patients in whose fusions BMP was used, there were 38 systemic complica- 
Discussion
Bone morphogenetic protein, specifically rhBMP-2, has been proven to increase the fusion rate in selected spinal fusion operations. However, complications such as seroma formation, tissue edema, and heterotopic bone formation have been attributed to BMP use. In the adult population these and other complications have been extensively studied, and controversy persists regarding the reported rate of adverse effects of BMP in adults. 4, 8 In children, there is no large, controlled study assessing potential adverse effects of BMP use. The FDA has not approved BMP use in children, and product labeling lists among the contraindications "age less than 18 or no radiographic evidence of epiphyseal closure." Bone morphogenetic protein plays an important role in skeletogenesis as well as in the development of various other tissues. 15 How surgical administration of BMP may influence the developing skeletal system (or any other immature organ system in children) is unknown.
In addition, BMP is a member of the transforming growth factor-beta family, dysregulation of which has been implicated in oncogenesis. Data from multiple studies pooled by the FDA showed a statistically insignificant increased cancer rate in patients with BMP exposure compared with those treated without BMP (http://www.fda.gov/ downloads/AdvisoryCommittees/Committees%20Meet ingMaterials/MedicalDevicesAdvisoryCommittee/Ortho paedicand%20RehabilitationDevicesPanel/UCM220081. pdf). Likewise, a re-evaluation of the publicly available data on high-dose rhBMP-2 (AMPLIFY; Medtronic, Inc.) shows a significant increase in the incidence of new cancer events at 2 years for patients exposed to BMP compared with controls (3.37 new cancer events per 100 person-years vs 0.50 events per 100 person-years). 3 Another administrative database study of more than 4000 patients found an increased risk of benign neoplasms with BMP exposure (OR 1.31, 95% CI 1.02-1.68), but not of malignancies. 11 None of these studies included pediatric patients, and the cancer risk for children has not been assessed. Importantly, the methodology of the present study did not allow for longterm follow-up, and thus cannot address cancer risk.
An extensive literature review confirmed the dearth of studies evaluating the safety of BMP in children. Three reports used large administrative databases to evaluate use of BMP in spinal fusion in children, and 2 of these studies assessed complications. Neither study showed a difference in complication rate with BMP use. Six single-institution studies reported a complication rate with BMP use from 0% to 18%, but all were retrospective and none included a control arm. From available data, conclusions about BMPrelated complications in children are hard to draw.
We have queried a large, private payer database and report the use of BMP in 37.61% of pediatric spinal fusions performed between 2005 and 2011. This rate of BMP utilization is markedly higher than the published rate of approximately 9% in previous studies based on administrative databases. 6, 10, 19 Previous work has suggested a higher use of BMP in patients covered by private insurance. 10 The current study is based on a database composed solely of patients from a single private insurance corporation. This is one factor that may contribute to the 4-fold increase in utilization. Other factors previously noted to be associated with BMP use, such as teaching hospital, region of the country, and presence of spondylolisthesis cannot be analyzed using this dataset. Dodwell, Snyder, and Wright found older age to be associated with increased BMP use. Although we are unable to report the ages of included patients, the majority of the patients in the present dataset are age 10-19 years. It is possible that age is another factor contributing to the high rate of BMP use. The purpose of this study has been to compare the rate of complication with BMP use to that of spinal fusion without BMP use. We have found no difference. Furthermore, there is no subgroup of patients for whom there is a noticeable or significant difference in the complication rate with versus without BMP use. Importantly, however, due to the small numbers, an analysis of the complications occurring after cervical spine fusions, either anterior or posterior, cannot be performed using this database. Previous work has suggested that a higher rate of complications is likely with BMP use in the cervical spine. 16 The overall complication rate of 9.8% is higher than what has previously been reported from administrative database research, but close to the rate reported by singleinstitution retrospective case series. We have been as inclusive as possible in our definition of complications and reoperation (see Tables 2 and 3) in an attempt to capture as many potential complications as possible. Because of this, it is not surprising that the complication rate in this study is higher than in previous database studies. Furthermore, unlike studies based on inpatient samples, our methodology allowed for the collection of complications occurring later than the initial hospitalization. This is important for the assessment of an agent like BMP, in which wound complication or neurological compromise from seroma or inflammation might become apparent after the initial hospital discharge.
Limitations of the Study
The PearlDiver database contains data from a single health care provider. Thus, the patients included probably share demographic and socioeconomic factors that are not quantified. The vast majority of patients are 10-19 years old, and most are girls. This severely limits the generalizability of this study to the pediatric population at large. United HealthCare insures individuals throughout the US, but we have no information about the geographic distribution or socioeconomic status of patients included in this database query. We have no information about the number of spinal levels fused, the indications for fusion, the exact surgical approach, the dose of BMP used, or the exact BMP product used (although it is presumed that the BMP product used is nearly exclusively rhBMP-2, or INFUSE). In addition, our methodology does not provide any way to determine if autologous bone is harvested for autograft. Presumably, the use of BMP would minimize the need for autologous bone graft harvest. Complications that result from the harvest of autograft would probably be higher in the group without BMP, but there is no way to evaluate this effect.
Ninety-day follow-up allows the identification of complications outside the initial hospitalization, but may miss long-term complications such as cancer. There is no method available to determine if a patient is lost to follow-up, nor is the rate of cohort maintenance available. The database is constructed from claims made to insurance, so a patient who has lost or changed coverage and then had a complication would not be captured. This limitation would apply to patients treated both with and without BMP, and would probably not represent a significant proportion of patients, given that this entire cohort is pediatric patients covered under parental insurance.
Complication identification is performed using ICD-9 codes. It is possible that this leads to underreporting due to missed codes or to overreporting on a hospital's part due to common efforts to maximize reporting of comorbid conditions. Although prospective data would be preferred, ICD-9 codes have been shown to be a reliable way to identify adverse events. 17, 18 A central assumption of this work is that the ICD-9 codes associated with the use of BMP are accurately reported. We believe that this assumption is valid given the high cost of BMP. This assumption has been made in similar large database studies of adult populations. 5 Since this database is drawn from an insurance provider who is ultimately paying for the use of BMP, we believe that the coding for BMP is likely to be correct. However, due to PearlDiver's privacy policy, no individual field can be populated if the total of patients is fewer than 11. This will result in failure to report low-frequency events that may bias the results. The primary objective of the use of BMP is to promote bony fusion. Since the length of follow-up in the present study is limited to 90 days, there is no way to assess the success of fusion; we are only able to assess short-term complications. Finally, some complications such as ectopic bone formation and radiculitis are difficult to capture using ICD-9 codes.
The only covariates available for analysis are age 10 or more years or less than 10 years, location of surgery, and sex. Comparison of complications within and between these subgroups yields no difference in complication rate. We are unable to perform more rigorous statistical analysis of risk due to small numbers of patients in the less than 10-year age group and in the cervical surgery groups.
The results of this study can be viewed as reassuring; increased rates of complications do not appear to occur in pediatric patients, although case reports of the use of BMP at the craniocervical junction show potential for significant neurological complications. The FDA considers this product to be contraindicated, and therefore the surgeon should only use it when absolutely needed. If used, the lowest dose possible to achieve the desired effect should be administered. Unfortunately, dosing has not been critically evaluated in pediatric patients and would be expected to vary by age and location of the fusion. Additionally, a proper informed consent should include a discussion of the offlabel risks of BMP use in pediatric patients.
Conclusions
We have queried a large administrative database to examine complications after spinal fusion in children with and without the use of BMP. Whereas we found utilization of BMP in this population to be surprisingly high, we found no difference in the rate of complication. It is apparent from this work and that of others that BMP is used frequently in pediatric spinal fusion. The present work suffers many limitations and cannot adequately address the safety of this agent in children. Although adverse effects of BMP use in children have been reported, they have not been adequately studied: prospective or registry-based assessments of outcomes are essential. Given the large numbers of spinal fusions performed each year in which BMP is used, accrual to such a study should be feasible and would contribute valuable information regarding both the beneficial and adverse effects of this biological agent on the young spine and the young patient.
